RAVICTI Oral Liquid

USDailyMed:Glycerol phenylbutyrate A16AX09(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-only 1,2,3-Propanetriyl tris(4-phenylbutanoate) 611168-24-2 10482134 DB08909 8657541 ZH6F1VCV7B D10127 ChEMBL2105745 DTXSID40210005 Interactive image C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3 InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4‍‍‍‍‍‍​​​‍​​​​​​-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2Key:ZSDBFLMJVAGKOU-UHFFFAOYSA-N Glycerol phenylbutyrate, sold under the brand nameRavicti, is a nitrogen-binding agentmedicationused for chronic management of certainurea cycle disorders. The medication reduces the harmful buildup ofammoniain the body.It functions as aprodrugofphenylbutyric acid, which conjugates withglutamineto formphenylacetylglutamine, facilitating ammonia excretion via the kidneys It was developed byHyperion Therapeuticsbased on the existing medicationsodium phenylbutyrate, and receivedFDAapproval in February 2013.